GLP-1R
53 programs · 50 companies
Programs
53
Companies
50
Active Trials
33
Targeting GLP-1R
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | MCC | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | IPF | |
| Tirzepatide | Eli Lilly | Approved | T2DObesity | |
| MRK-5413 | Merck & Co | Phase 1 | NASHWM | |
| Voxacilimab | AstraZeneca | Phase 1/2 | NB | |
| AZN-5171 | AstraZeneca | Approved | RSVPV | |
| Mavuglumide | Bayer | Approved | MCL | |
| Bemarelsin | Daiichi Sankyo | Preclinical | PV | |
| VRT-5441 | Vertex Pharma | Phase 3 | NB | |
| ZYM-2450 | Zymeworks | Phase 2 | IPFCrohn's | |
| 600-1653 | Jiangsu Hengrui | NDA/BLA | ASPBC | |
| Sotoratamab | Sun Pharma | Phase 2 | PNHCLL | |
| 209-6556 | Simcere | Preclinical | HSOvarian Ca | |
| DAN-IIT-371 | Dana-Farber | Phase 3 | CSU | |
| MAY-IIT-825 | Mayo Clinic | Approved | RA | |
| SAM-IIT-637 | Samsung Medical Ctr | Phase 2/3 | FTD | |
| SEO-IIT-935 | Seoul Natl Univ Hosp | Phase 2/3 | Asthma | |
| PEK-IIT-794 | Peking Univ Cancer Hosp | Phase 1/2 | Obesity | |
| MIR-8648 | Mirati (BMS) | Phase 1/2 | ThymomaEwing Sarcoma | |
| CAR-6194 | Carmot (Roche) | Preclinical | AsthmaHCC | |
| TES-3466 | Tessera Ther | NDA/BLA | Alzheimer'sFSGS | |
| Voxazanubrutinib | GenEdit | Preclinical | SCLCFSGS | |
| Datofutibatinib | Prelude | Approved | ALSGBM | |
| PBL-8716 | Panbela Therapeutics | Preclinical | SCDMigraine | |
| Kemanesiran | Loxo (Lilly) | Phase 1 | Wet AMDRett | |
| Doxarasimod | Synthorx (Sanofi) | Phase 3 | CTCLCSU | |
| Mavubrutinib | Forty Seven (Gilead) | Phase 3 | Urothelial CaFL | |
| 109-3699 | CSPC Pharma | Phase 2 | CML | |
| ASK-5918 | Asklepios | Phase 2/3 | DravetSLE | |
| REM-8705 | Remix Ther | Preclinical | ACCALL | |
| Rilucapivasertib | Immunai | Phase 2/3 | AML | |
| Mavurapivir | Insitro | Phase 1 | FTDSLE | |
| GEN-IIT-455 | Genethon | Phase 2/3 | MS | |
| GEN-IIT-346 | Genethon | Approved | Bladder Ca | |
| GEN-IIT-414 | Genethon | NDA/BLA | PsA | |
| HYK-8507 | Hyku Bio | Phase 1 | WMGBM | |
| 415-3897 | Kyowa Kirin | Phase 3 | Ewing SarcomaMG | |
| Tiravorutinib | Meiji Pharma | Preclinical | CRCGastric Ca | |
| Pemizasiran | Windlas Bio | NDA/BLA | GBM | |
| MOR-4433 | Morphic (Lilly) | Phase 1/2 | MMHCC | |
| CAL-5800 | Calliditas | Phase 1/2 | MelanomaHeart Failure | |
| Fixacagene | Polynovo | Approved | Endometrial CaMM | |
| Elracagene | Exact Sciences | NDA/BLA | MGFSGS | |
| DAR-2860 | Dare Bioscience | Phase 1 | FabryMS | |
| IDI-7416 | Idorsia | Phase 2 | HNSCCOvarian Ca | |
| EVO-5421 | Evolva | Preclinical | Asthma | |
| Cevisacituzumab | Philogen | Preclinical | MesoAtopic Derm | |
| KLB-5656 | Kalbe Farma | Phase 1 | Cholangiocarcinoma | |
| CAN-IIT-971 | Cancer Hosp CAMS | Approved | IPF | |
| CYB-1519 | Cybin | Phase 2/3 | Prostate CaMCL | |
| AMY-7405 | Amyris | Phase 1/2 | MDSEoE | |
| MED-9563 | Medicago (PMI) | Approved | Prostate Ca | |
| QTR-9473 | Quanterix | Approved | CTCLHeart Failure |